Cambridge Investment Research Advisors, Inc. Humacyte, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Humacyte, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 13,300 shares of HUMA stock, worth $58,653. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,300
Previous 11,027
20.61%
Holding current value
$58,653
Previous $53,000
35.85%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding HUMA
# of Institutions
150Shares Held
35.1MCall Options Held
279KPut Options Held
607K-
Black Rock Inc. New York, NY7.14MShares$31.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.06MShares$22.3 Million0.0% of portfolio
-
State Street Corp Boston, MA4.76MShares$21 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.04MShares$9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.27MShares$5.59 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $454M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...